Spots Global Cancer Trial Database for Effect of Neomycin on the Pharmacokinetics of Regorafenib
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Effect of Neomycin on the Pharmacokinetics of Regorafenib
Official Title: Single-center, Open-label, Non-randomized, Two-period Sequential Treatment Study to Assess the Effect of Neomycin on the Pharmacokinetics of Regorafenib in Healthy Male Subjects
Study ID: NCT02001909
Conditions
Study Description
Brief Summary: To investigate the effect of neomycin on the pharmacokinetics (PK) of regorafenib in healthy male subjects
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT
Sex: MALE
Healthy Volunteers: Yes
Locations
, Berlin, , Germany
Contact Details
Name: Bayer Study Director
Affiliation: Bayer
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
